Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lee, Hee Jung ^a   Hur, Yoon Ki ^a   Cho, Youn Dong ^a   Kim, Mi Gyeong ^b   Lee, Hoon Taek ^a   Oh, Yu Kyoung ^b   Kim, Young Bong ^a  

^a Konkuk University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VECTOR; DNA VACCINE; GAMMA INTERFERON; WART VIRUS VACCINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; SWINE; VIRION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; WART VIRUS;

ANIMALS; BACULOVIRIDAE; ENDOGENOUS RETROVIRUSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PAPILLOMAVIRUS VACCINES; RETROVIRIDAE; SWINE; VACCINES, DNA;

HUMAN ENDOGENOUS RETROVIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS; SUIDAE;

EID: 84870265742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050296     Document Type: Article

References (35)

1. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53: 296-302.
2. Liu MA, (2010) Immunologic basis of vaccine vectors. Immunity 33: 504-515.
3. Bodles-Brakhop AM, Draghia-Akli R, (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7: 1085-1101.
4. Bolhassani A, Safaiyan S, Rafati S, (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10: 3.
5. Chen CY, Liu HJ, Tsai CP, Chung CY, Shih YS, et al. (2010) Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 28: 7644-7651.
6. Cho HJ, Han SE, Im S, Lee Y, Kim YB, et al. (2011) Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16 L1 protein and DNA as a vaccine co-delivery system. Biomaterials 32: 4621-4629.
7. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, et al. (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27: 5450-5459.
8. Ohlschläger P, Spies E, Alvarez G, Quetting M, Groettrup M, (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128: 473-481.
9. Brandsma JL, Shlyankevich M, Zhang L, Slade MD, Goodwin EC, et al. (2004) Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol 78: 116-123.
10. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8: 3676-3685.
11. Cho HJ, Oh YK, Kim YB, (2011) Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat 21: 295-309.
12. Lee HJ, Park N, Cho HJ, Yoon JK, Van ND, et al. (2010) Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 28: 1613-1619.
13. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, et al. (2009) Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 101: 475-487.
14. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, et al. (2011) Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 83: 1345-1350.
15. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, et al. (2006) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24: 5235-5244.
16. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT, (2005) Maturation of papillomavirus capsids. J Virol 79: 2839-2846.
17. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
18. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.
19. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D, (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85: 13253-13259.
20. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, et al. (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22: 3004-3007.
21. Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, et al. (2012) Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in Rhesus macaques. Hum Gene Ther 23: 733-741.
22. Garland SM, Smith JS, (2010) Human papillomavirus vaccines: current status and future prospects. Drugs 70: 1079-1098.
23. Pomfret TC, Gagnon JM Jr, Gilchrist AT, (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 36: 1-9.
24. Mejia AF, Culp TD, Cladel NM, Balogh KK, Budgeon LR, et al. (2006) Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol 80: 12393-12397.
25. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, et al. (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2. J Virol 81: 11585-11592.
26. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, et al. (1996) Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 173: 314-320.
27. Sundaram P, Tigelaar RE, Brandsma JL, (1997) Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine 15: 664-671.
28. Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, et al. (2002) Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76: 8900-8909.
29. Hu J, Cladel NM, Budgeon LR, Reed CA, Pickel MD, et al. (2006) Protective cell-mediated immunity by DNA vaccination against papillomavirus L1 capsid protein in the cottontail rabbit papillomavirus model. Viral Immunol 19: 492-507.
30. Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L, et al. (2001) Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19: 2783-2792.
31. Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, et al. (2011) Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy 31: 280-297.
32. Chen J, Ni G, Liu XS, (2011) Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 269: 5-9.
33. Liu L, Wang S, Shan B, Sang M, Liu S, et al. (2010) Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine 28: 3883-3887.
34. Brave A, Ljungberg K, Wahren B, Liu MA, (2007) Vaccine delivery methods using viral vectors. Mol Pharm 4: 18-32.
35. Hung CF, Ma B, Monie A, Tsen SW, Wu TC, (2008) Therapeutic human papillomavirus vaccines:current clinical trials and future directions. Expert Opin Biol Ther 8: 421-439.